Targeting ubiquitin signaling for cancer immunotherapy

Xiaofei Zhou; Shao Cong Sun

doi:10.1038/s41392-020-00421-2

Targeting ubiquitin signaling for cancer immunotherapy

Xiaofei Zhou, Shao Cong Sun

Immunology

Research output: Contribution to journal › Review article › peer-review

36 Scopus citations

Abstract

Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development and clinical application of immune checkpoint inhibitors represent one of the most extraordinary accomplishments in cancer immunotherapy. In addition, considerable progress is being made in understanding the mechanism of antitumor immunity and characterizing novel targets for developing additional therapeutic approaches. One active area of investigation is protein ubiquitination, a post-translational mechanism of protein modification that regulates the function of diverse immune cells in antitumor immunity. Accumulating studies suggest that E3 ubiquitin ligases and deubiquitinases form a family of potential targets to be exploited for enhancing antitumor immunity in cancer immunotherapy.

Original language	English (US)
Article number	16
Journal	Signal Transduction and Targeted Therapy
Volume	6
Issue number	1
DOIs	https://doi.org/10.1038/s41392-020-00421-2
State	Published - Dec 2021

ASJC Scopus subject areas

Genetics
Cancer Research

Access to Document

10.1038/s41392-020-00421-2

Cite this

@article{faf88914f4884972b472fd0d159476f7,

title = "Targeting ubiquitin signaling for cancer immunotherapy",

abstract = "Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development and clinical application of immune checkpoint inhibitors represent one of the most extraordinary accomplishments in cancer immunotherapy. In addition, considerable progress is being made in understanding the mechanism of antitumor immunity and characterizing novel targets for developing additional therapeutic approaches. One active area of investigation is protein ubiquitination, a post-translational mechanism of protein modification that regulates the function of diverse immune cells in antitumor immunity. Accumulating studies suggest that E3 ubiquitin ligases and deubiquitinases form a family of potential targets to be exploited for enhancing antitumor immunity in cancer immunotherapy.",

author = "Xiaofei Zhou and Sun, {Shao Cong}",

note = "Funding Information: Work in the authors{\textquoteright} laboratory is supported by grants from the US National Institutes of Health (AI057555, AI064639, and GM84459) and Cancer Prevention and Research Institute of Texas (RP190287). Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2021",

month = dec,

doi = "10.1038/s41392-020-00421-2",

language = "English (US)",

volume = "6",

journal = "Signal Transduction and Targeted Therapy",

issn = "2095-9907",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Targeting ubiquitin signaling for cancer immunotherapy

AU - Zhou, Xiaofei

AU - Sun, Shao Cong

N1 - Funding Information: Work in the authors’ laboratory is supported by grants from the US National Institutes of Health (AI057555, AI064639, and GM84459) and Cancer Prevention and Research Institute of Texas (RP190287). Publisher Copyright: © 2020, The Author(s).

PY - 2021/12

Y1 - 2021/12

N2 - Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development and clinical application of immune checkpoint inhibitors represent one of the most extraordinary accomplishments in cancer immunotherapy. In addition, considerable progress is being made in understanding the mechanism of antitumor immunity and characterizing novel targets for developing additional therapeutic approaches. One active area of investigation is protein ubiquitination, a post-translational mechanism of protein modification that regulates the function of diverse immune cells in antitumor immunity. Accumulating studies suggest that E3 ubiquitin ligases and deubiquitinases form a family of potential targets to be exploited for enhancing antitumor immunity in cancer immunotherapy.

AB - Cancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development and clinical application of immune checkpoint inhibitors represent one of the most extraordinary accomplishments in cancer immunotherapy. In addition, considerable progress is being made in understanding the mechanism of antitumor immunity and characterizing novel targets for developing additional therapeutic approaches. One active area of investigation is protein ubiquitination, a post-translational mechanism of protein modification that regulates the function of diverse immune cells in antitumor immunity. Accumulating studies suggest that E3 ubiquitin ligases and deubiquitinases form a family of potential targets to be exploited for enhancing antitumor immunity in cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85099200342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099200342&partnerID=8YFLogxK

U2 - 10.1038/s41392-020-00421-2

DO - 10.1038/s41392-020-00421-2

M3 - Review article

C2 - 33436547

AN - SCOPUS:85099200342

SN - 2095-9907

VL - 6

JO - Signal Transduction and Targeted Therapy

JF - Signal Transduction and Targeted Therapy

IS - 1

M1 - 16

ER -

Targeting ubiquitin signaling for cancer immunotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this